Colinz Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 621096,
    "name": "Colinz Labs",
    "stock_name": "Colinz Labs",
    "full_name": "Colinz Laboratories Ltd",
    "name_url": "stocks-analysis/colinz-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "46.80",
    "chg": 1.9,
    "chgp": "4.23%",
    "dir": 1,
    "prev_price": "44.90",
    "mcapval": "11.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531210,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE923C01011",
    "curr_date": "Mar 19",
    "curr_time": "",
    "bse_nse_vol": "3.39 k",
    "exc_status": "Active",
    "traded_date": "Mar 19, 2026",
    "traded_date_str": "2026 03 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/colinz-labs-621096-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Colinz Laboratories Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3895830",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ColinzLaborator_mojoScore_3895830.png",
        "date": "2026-03-17 08:06:46",
        "description": "Colinz Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Mar 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite a micro-cap status and an attractive valuation on price-to-book metrics, the company’s financial trends and technical signals have worsened, prompting a reassessment of its investment appeal."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Improved Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-improved-price-attractiveness-3851973",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ColinzLaborator_valuationdot_3851973.png",
        "date": "2026-02-24 08:01:28",
        "description": "Colinz Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite recent volatility in its share price and mixed returns relative to the broader market. This change reflects improved price-to-earnings and price-to-book value metrics, positioning the pharmaceutical and biotechnology firm as a potentially compelling investment within its sector."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-3836484",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ColinzLaborator_valuationdot_3836484.png",
        "date": "2026-02-13 08:01:41",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from fair to attractive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, suggests a recalibration of price attractiveness amid a challenging market backdrop and evolving sector dynamics."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts to Fair Amidst Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-to-fair-amidst-mixed-market-signals-3821567",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ColinzLaborator_valuationdot_3821567.png",
        "date": "2026-02-05 08:01:06",
        "description": "Colinz Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with its recent market performance and peer comparisons, offers investors a fresh perspective on the stock’s price attractiveness amid a challenging industry backdrop."
      },
      {
        "title": "Colinz Laboratories Ltd Forms Golden Cross, Signalling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-forms-golden-cross-signalling-potential-bullish-breakout-3808158",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ColinzLaborator_goldencross_3808158.png",
        "date": "2026-01-28 18:00:15",
        "description": "Colinz Laboratories Ltd has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-day moving average. This development often signals a potential bullish breakout, indicating a possible trend reversal and a shift towards long-term upward momentum for the pharmaceutical and biotechnology company."
      },
      {
        "title": "Are Colinz Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-colinz-laboratories-ltd-latest-results-good-or-bad-3804346",
        "imagepath": "",
        "date": "2026-01-25 19:11:24",
        "description": "Colinz Laboratories Ltd's latest financial results for Q3 FY26 reveal a complex operational landscape characterized by contrasting trends in revenue and profitability. The company reported net sales of ₹1.43 crores, reflecting a quarter-on-quarter increase of 2.88%. However, this modest growth is overshadowed by a significant decline in net profit, which fell to ₹0.08 crores, representing a 42.86% decrease from the previous quarter. \n\nThe profit after tax (PAT) margin also saw a notable contraction, dropping to 5.59% from 10.07% in the prior quarter, indicating challenges in maintaining operational efficiency and cost management. While the operating margin improved slightly to 6.99%, it remains below previous levels, highlighting ongoing issues with profitability.\n\nYear-on-year comparisons further illustrate the company's struggles, as revenue decreased by 2.72% from ₹1.47 crores in Q3 FY25. This trend of d..."
      },
      {
        "title": "Colinz Laboratories Q3 FY26: Marginal Revenue Growth Masks Deeper Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/colinz-laboratories-q3-fy26-marginal-revenue-growth-masks-deeper-profitability-concerns-3803825",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ColinzLaborator_quaterlyResult_3803825.png",
        "date": "2026-01-24 21:31:19",
        "description": "Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported a modest quarterly performance for Q3 FY26, with net profit declining 42.86% quarter-on-quarter to ₹0.08 crores from ₹0.14 crores in Q2 FY26. On a year-on-year basis, net profit increased 60.00% from ₹0.05 crores in Q3 FY25, though this comparison benefits from an exceptionally weak base quarter. With a market capitalisation of just ₹13.00 crores, the Mumbai-based company continues to struggle with scale and profitability consistency, as reflected in its current stock price of ₹46.20, down 47.91% from its 52-week high of ₹88.70."
      },
      {
        "title": "Colinz Laboratories Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-ltd-is-rated-strong-sell-3771259",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ColinzLaborator_mojoScore_3771259.png",
        "date": "2025-12-26 15:12:03",
        "description": "Colinz Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 June 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 599,
    "sid": "621096",
    "stock_news_url": "https://www.marketsmojo.com/news/colinz-laboratories-621096"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "28-Jan-2026",
      "details": "Dear Sir As required under Regulation 47(3) of SEBI (LODR) Regulations 2015. Please find the attached News Paper Publication made towards our issued Quarterly Results for Dec-25. Kindly take the same on records. For Colinz Labs Ltd Director",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.",
      "datetime": "24-Jan-2026",
      "details": "We would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 24th January 2026 has inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the Quarter and Nine Months Ended on 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.",
      "datetime": "24-Jan-2026",
      "details": "As required under Regulations 30 and 33 we are attaching herewith the our Quarterly Results as on Dec-2025. Kindly take the same on records. Directors",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Colinz Laboratories Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-03-17 08:06:46

Colinz Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Mar 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite a micro-cap status and an attractive valuation on price-to-book metrics, the company’s financial trends and technical signals have worsened, prompting a reassessment of its investment appeal.

Read full news article

Colinz Laboratories Ltd Valuation Shifts Signal Improved Price Attractiveness

2026-02-24 08:01:28

Colinz Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite recent volatility in its share price and mixed returns relative to the broader market. This change reflects improved price-to-earnings and price-to-book value metrics, positioning the pharmaceutical and biotechnology firm as a potentially compelling investment within its sector.

Read full news article

Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-02-13 08:01:41

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from fair to attractive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, suggests a recalibration of price attractiveness amid a challenging market backdrop and evolving sector dynamics.

Read full news article

Colinz Laboratories Ltd Valuation Shifts to Fair Amidst Mixed Market Signals

2026-02-05 08:01:06

Colinz Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with its recent market performance and peer comparisons, offers investors a fresh perspective on the stock’s price attractiveness amid a challenging industry backdrop.

Read full news article

Colinz Laboratories Ltd Forms Golden Cross, Signalling Potential Bullish Breakout

2026-01-28 18:00:15

Colinz Laboratories Ltd has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-day moving average. This development often signals a potential bullish breakout, indicating a possible trend reversal and a shift towards long-term upward momentum for the pharmaceutical and biotechnology company.

Read full news article

Are Colinz Laboratories Ltd latest results good or bad?

2026-01-25 19:11:24

Colinz Laboratories Ltd's latest financial results for Q3 FY26 reveal a complex operational landscape characterized by contrasting trends in revenue and profitability. The company reported net sales of ₹1.43 crores, reflecting a quarter-on-quarter increase of 2.88%. However, this modest growth is overshadowed by a significant decline in net profit, which fell to ₹0.08 crores, representing a 42.86% decrease from the previous quarter. The profit after tax (PAT) margin also saw a notable contraction, dropping to 5.59% from 10.07% in the prior quarter, indicating challenges in maintaining operational efficiency and cost management. While the operating margin improved slightly to 6.99%, it remains below previous levels, highlighting ongoing issues with profitability. Year-on-year comparisons further illustrate the company's struggles, as revenue decreased by 2.72% from ₹1.47 crores in Q3 FY25. This trend of d...

Read full news article

Colinz Laboratories Q3 FY26: Marginal Revenue Growth Masks Deeper Profitability Concerns

2026-01-24 21:31:19

Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported a modest quarterly performance for Q3 FY26, with net profit declining 42.86% quarter-on-quarter to ₹0.08 crores from ₹0.14 crores in Q2 FY26. On a year-on-year basis, net profit increased 60.00% from ₹0.05 crores in Q3 FY25, though this comparison benefits from an exceptionally weak base quarter. With a market capitalisation of just ₹13.00 crores, the Mumbai-based company continues to struggle with scale and profitability consistency, as reflected in its current stock price of ₹46.20, down 47.91% from its 52-week high of ₹88.70.

Read full news article

Colinz Laboratories Ltd is Rated Strong Sell

2025-12-26 15:12:03

Colinz Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 June 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

View All News